IRONWOOD PHARMACEUTICALS INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $296.2M | $351.4M | $442.7M | $410.6M | $413.8M |
| Operating income | $98.5M | $93.1M | -$945.4M | $250.3M | $232.3M |
| Cash from operations | $127.0M | $103.5M | $183.4M | $273.8M | $261.9M |
| Capital expenditure | $34,000 | $142,000 | $273,000 | $136,000 | $265,000 |
| Free cash flow | $127.0M | $103.4M | $183.2M | $273.6M | $261.6M |
| Share repurchases | — | — | $123.4M | $126.4M | $24.1M |
| Total assets | $396.9M | $350.9M | $471.1M | $1.1B | $1.1B |
| Total debt | — | — | — | $412.8M | $539.3M |
Shares outstanding 164.6M · Free float 90.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.